Patents Examined by Sheela J. Huff
  • Patent number: 9950078
    Abstract: Conjugates of specific PBD dimers with an antibody that that binds to CD19, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 2, 3, 4, 5 or 6, optionally further comprising a VL domain having the sequence according to any one of SEQ ID NOs. 7, 8, 9, 10, 11 or 12.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: April 24, 2018
    Assignee: Medimmune Limited
    Inventors: Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
  • Patent number: 9950048
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: April 24, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Harpreet Singh, Steffen Walter, Toni Weinschenk, Norbert Hilf, Oliver Schoor, Claudia Trautwein
  • Patent number: 9951133
    Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: April 24, 2018
    Assignee: GENENTECH, INC.
    Inventors: Shang-Fan Yu, Wei-Ching Liang, Yan Wu, Steven Leong, Andrew Polson
  • Patent number: 9943537
    Abstract: Provided is a novel method for treating a cancer using an FTD/TPI combination drug, which shows remarkably excellent antitumor effect and small adverse effects. An antitumor agent, in which a combination drug containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 and an anti-VEGF antibody or anti-EGFR antibody are administered in combination.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: April 17, 2018
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Hiroyuki Okabe
  • Patent number: 9931415
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: April 3, 2018
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS S.A.
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Patent number: 9931414
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: April 3, 2018
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS S.A.
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Patent number: 9926376
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: March 27, 2018
    Assignees: Agensys, Inc., Seattle Genetics Inc.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Patent number: 9925273
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 27, 2018
    Assignee: AGENSYS, INC.
    Inventors: Daniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
  • Patent number: 9920121
    Abstract: The present disclosure provides a human antibody or antigen binding fragment thereof or an antibody construct comprising a human binding domain or antigen binding fragment thereof capable of binding to human CDH19 on the surface of a target cell. The disclosure relates to a nucleic acid sequence encoding the antibody or antigen binding fragment thereof contained in the antibody construct, a vector comprising the nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the disclosure relates to a process for the production of the antibody construct of the disclosure, a medical use or a method of treatment using the antibody construct and a kit comprising the antibody or antigen binding fragment thereof or the antibody construct.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 20, 2018
    Assignee: AMGEN INC.
    Inventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan
  • Patent number: 9919056
    Abstract: Conjugates of an isolated humanized, anti-CD22 antibody with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: March 20, 2018
    Assignees: ADC THERAPEUTICS S.A., MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Patent number: 9914752
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: March 13, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Gary S. Jacob
  • Patent number: 9913885
    Abstract: Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: March 13, 2018
    Inventors: David Weiner, Jian Yan, Bernadette Ferraro, Niranjan Y. Sardesai, Mathura P. Ramanathan
  • Patent number: 9914768
    Abstract: The present invention relates to the use of antibodies against S100A7 protein for the prevention and/or treatment of cancer or a disease associated to an undesired angiogenesis or a disease associated with inflammation; and to methods and kits for diagnosing and determining the prognostic of said diseases in vitro and in vivo by means of detecting levels of S100A7 in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100A7 monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as pharmaceutical compositions and conjugates containing them.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: March 13, 2018
    Assignee: Lykera Biomed, S.A.
    Inventors: José Luis Hernández Míguez, Jaume Adan Plana, Josep Maria Martínez Escolà, Marc Masa Álvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla García, Lourdes Tatiana Roque Navarro, Laura Barberà Ferrando, Manuel Rivas Cañas
  • Patent number: 9909108
    Abstract: Disclosed are therapeutic formulations comprising antibodies against the PEKRAEKIWK (SEQ ID NO:1) epitope of the monomeric isoform of A-protein and a physiologically acceptable carrier. Methods for the treatment of subjects using these therapeutic formulations are also disclosed.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 6, 2018
    Assignee: ASK DIAGNOSTICS, INC.
    Inventor: Geoffrey Schmidt
  • Patent number: 9907768
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: March 6, 2018
    Assignee: IO THERAPEUTICS, INC.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 9908920
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 6, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
  • Patent number: 9895439
    Abstract: Pharmaceutical composition comprising a chemotherapeutic drug and a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug in vivo, in a pharmaceutically acceptable carrier or vehicle. The chemotherapeutic drug is selected from those able to induce over expression of netrin-1 in cancer cells. The combination is associated with synergic anti-cancer effect.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: February 20, 2018
    Assignee: NETRIS PHARMA
    Inventors: Patrick Mehlen, Andréa Paradisi, Pascale Nony
  • Patent number: 9889159
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: February 13, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Janet Peper, Philipp Wagner, Hans-Georg Rammensee
  • Patent number: 9879065
    Abstract: The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: January 30, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Xin Yao
  • Patent number: 9872922
    Abstract: The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: January 23, 2018
    Assignees: Pfizer Inc., AbbVie Stemcentrx LLC
    Inventors: Marc Isaac Damelin, Kiran Manohar Khandke, Puja Sapra, Alexander John Bankovich, Scott J. Dylla